AKORN INC Form SC 13D/A April 20, 2009 UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE 13D

SCHEDULE 13D				
Under the Securities Exchange Act of 1934				
(Amendment No. 16)*				
Akorn, Inc.				
(Name of Issuer)				
Common Stock, no par value				
(Title of Class of Securities)				
009728 10 6				
(Cusip Number)				
	Сору	m		
John N. Kapoor	То:	Thomas J. Murphy		
EJ Financial Enterprises, Inc. 225 E. Deerpath, Suite 250		McDermott, Will & Emery 227 West Monroe Street		
Lake Forest, IL 60045		Chicago, IL 60606		
847-295-8665		312-984-2069		

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

April 13, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box //.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

#### SCHEDULE 13D

1	Names of Reporting Persons: John N. Kapoor Trust, dtd 9/20/89			entities only):
2	Check the Appro (a) /X/ (b) //		a if a Member of a Group (See Instructions):	
3	SEC Use Only:			
4	Source of Funds OO (See Item 3)		action):	
5	Check if Disclos	ure of Leg	al Proceedings is Required Pursuant to Items 2(d) or 2(e):	//
6	Citizenship or Pl Illinois	ace of Org	anization:	
	4.61	7	Sole Voting Power: 26,535,829*	
Bei	er of Shares neficially aned by	8	Shared Voting Power: -0-	
	oorting son	9	Sole Dispositive Power: 26,535,829*	
		10	Shared Dispositive Power: -0-	
11 26,535		ınt Benefic	cially Owned by Each Reporting Person:	
12	Check if the Agg	regate Am	nount in Row (11) Excludes Certain Shares (See Instructions):	//
13			ed by Amount in Row (11): ,481 shares of common stock outstanding*	

14	Type of Reporting Person (See Instructions): OO
*Include	s an immediately exercisable Warrant for 1,501,933 shares of Common Stock.

1	Names of Reporting Persons: John N. Kapoor		ns: I.R.S. Identification Nos. of Above Persons (	entities only):
2	Check the Appr (a) /X (b) //		x if a Member of a Group (See Instructions):	
3	SEC Use Only:			
4	Source of Fund	s (See Instr	uction):	
5	Check if Disclo Citizenship or F USA		gal Proceedings is Required Pursuant to Items 2(d) or 2(e): ganization:	//
	6.01	7	Sole Voting Power: 27,160,441 <sup>1</sup>	
Be O	oer of Shares eneficially wned by ach	8	Shared Voting Power: 4,985,283 <sup>2</sup>	
Re Pe	eporting erson (ith	9	Sole Dispositive Power: 27,160,441 <sup>1</sup>	
		10	Shared Dispositive Power: 4,985,283 <sup>2</sup>	
11 32,14	Aggregate Amo	ount Benefi	cially Owned by Each Reporting Person:	
12	Check if the Ag	gregate An	nount in Row (11) Excludes Certain Shares (See Instructions)	/X/
13			ted by Amount in Row (11): 5,120 shares of common stock deemed outstanding <sup>12</sup>	
14	Type of Reporti	ng Person	(See Instructions):	

\_\_\_\_\_

 $<sup>^{1}</sup>$  Includes an immediately exercisable Warrant for 1,501,933 shares of Common Stock.

 $<sup>^2\,\</sup>mathrm{Includes}$  an immediately exercisable Warrant for 1,939,639 shares of Common Stock.

1	Names of Reporting Persons: EJ Financial/Akorn Management, L.P.			I.R.S. Identification Nos. of Above Persons (entities only)	
2	Check the Appro (a) /X. (b) //		a if a Member of a Group (See Instructions):		
3	SEC Use Only:				
4	Source of Funds OO	(See Instr	uction):		
5	Check if Disclos	sure of Leg	al Proceedings is Required Pursuant to Items 2(d) or 2(e):	//	
6	Citizenship or P Illinois	lace of Org	ganization:		
Num	show of Chanco	7	Sole Voting Power: -0-		
Number of Shares Beneficially Owned by Each		8	Shared Voting Power: 3,045,644		
R P	Reporting Person Vith	9	Sole Dispositive Power: -0-		
		10	Shared Dispositive Power: 3,045,644		
11 3,04	Aggregate Amor	unt Benefic	cially Owned by Each Reporting Person:		
12	Check if the Agg	gregate An	nount in Row (11) Excludes Certain Shares (See Instructions):	//	
13		Percent of Class Represented by Amount in Row (11): 3.3794% based on 90,124,548 shares of common stock outstanding			
14		Type of Reporting Person (See Instructions) PN			

1	Names of Reporting Persons: Pharma Nevada, Inc.		is: I.R.S. Identification Nos. of Above Persons (en	I.R.S. Identification Nos. of Above Persons (entities only)	
2	Check the Appr (a) /X (b) //	<i>_</i>	x if a Member of a Group (See Instructions):		
3	SEC Use Only:				
4	Source of Funds	(See Instru	action):		
5	Check if Disclos	sure of Leg	al Proceedings is Required Pursuant to Items 2(d) or 2(e):	//	
6	Citizenship or P Illinois	lace of Org	anization:		
NT .		7	Sole Voting Power: -0-		
B O	ber of Shares eneficially wned by ach	8	Shared Voting Power: 3,045,644		
R Po	eporting erson /ith	9	Sole Dispositive Power: -0-		
		10	Shared Dispositive Power: 3,045,644		
11 3,045		unt Benefic	cially Owned by Each Reporting Person:		
12	Check if the Ag	gregate An	nount in Row (11) Excludes Certain Shares (See Instructions):	//	
13		Percent of Class Represented by Amount in Row (11): 3.3794% based on 90,124,548 shares of common stock outstanding			
14	Type of Reporti	Type of Reporting Person (See Instructions)			

1	Names of Reporting Persons: EJ Funds LP		is: I.R.S. Identification Nos. of Above Persons (	I.R.S. Identification Nos. of Above Persons (entities only)	
2	Check the Appr (a) /X (b) //	/	a if a Member of a Group (See Instructions):		
3	SEC Use Only:				
4	Source of Funds	s (See Instr	uction):		
5	Check if Disclo	sure of Leg	al Proceedings is Required Pursuant to Items 2(d) or 2(e):	//	
6	Citizenship or P Illinois	lace of Org	ganization:		
Numb	per of Shares	7	Sole Voting Power: -0-		
Number of Shares Beneficially Owned by Each		8	Shared Voting Power: 1,939,639*		
Re Pe	eporting rson ith	9	Sole Dispositive Power: -0-		
		10	Shared Dispositive Power: 1,939,639*		
11 1,939	Aggregate Amo	unt Benefic	cially Owned by Each Reporting Person:		
12	Check if the Ag	gregate An	nount in Row (11) Excludes Certain Shares (See Instructions):	//	
13		Percent of Class Represented by Amount in Row (11): 2.1068% based on 92,064,187 shares of common stock deemed outstanding*			
14	Type of Reporti	ng Person (	(See Instructions)		

<sup>(</sup> Consists of an immediately exercisable Warrant for 1,939,639 shares of Common Stock.	

Note:

As more fully described in Item 4 below, this Amendment No. 16 (this "Amendment") to Schedule 13D is being filed to disclose events not previously required to be disclosed including a pro rata distribution of Akorn Common Stock in March of 2007 and three open market purchases of Akorn Common Stock in March of 2008. This Amendment also discloses current acquisitions by a new affiliate of John N. Kapoor and the Trust of two Warrants for Akorn Common Stock in April of 2009.

This Amendment is filed jointly by (i) the Trust, of which John N. Kapoor is trustee and sole beneficiary, (ii) John N. Kapoor, (iii) EJ Financial/Akorn Management, L.P., a Delaware limited partnership (EJ/Akorn) of which Pharma Nevada, Inc. is the managing general partner, (iv) Pharma Nevada, Inc., a Nevada corporation wholly owned by John N. Kapoor of which John N. Kapoor serves as the president and chairman of the board of directors, and (v) EJ Funds LP, a Delaware Limited Partnership (collectively, the Reporting Persons).

#### Item 2 Identify and Background

Item 2 is hereby amended by adding the following information:

- (a) Name: EJ Funds LP, a Delaware Limited Partnership; EJ Financial Enterprises, Inc. is the general partner and John N. Kapoor is the owner of EJ Financial Enterprises, Inc.
- (b) Business Address: 225 East Deerpath, Suite 250

Lake Forest, IL 60045

- (d) During the past five years, such person has not been convicted in a criminal proceeding.
- (e) During the past five years, such person has not been a party to a civil proceeding of a judicial or an administrative body of competent jurisdiction resulting or subjecting such person to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

#### Item 4. Purpose of Transaction

On March 14, 2007, there was a pro rata distribution from a limited partnership controlled by John N. Kapoor of 158.493 shares of Akorn Common Stock.

On March 14, 2008, the Reporting Persons acquired 5,000 shares of Akorn Common Stock in an open market purchase at \$4.51 per share. On March 19, 2008, the Reporting Persons acquired 5,000 shares of Akorn Common Stock in an open market purchase at \$4.6589 per share. On March 20, 2008, the Reporting Persons acquired 40,000 shares of Akorn Common Stock in an open market purchase at \$4.6721 per share.

Pursuant to a Modification, Warrant and Investor Rights Agreement, dated April 13, 2009 (the "Modification Agreement") EJ Funds LP acquired an immediately exercisable Warrant (right to buy) 1,939,639 shares of Akorn Common Stock at \$1.11 per share. This Warrant will expire on April 13, 2014. A copy of the Modification Agreement is attached as an exhibit to this Amendment.

Pursuant to a Reimbursement and Warrant Agreement, dated April 15, 2009 (the Reimbursement Agreement ) the Trust acquired an immediately exercisable Warrant (right to buy) 1,501,933 shares of Akorn Common Stock at \$1.11 per share. This Warrant will expire on April 15, 2014. A copy of the Reimbursement Agreement is attached as an exhibit to this Amendment.

The Reporting Persons have acquired the Akorn Common Stock and Warrants described above as an investment and intend to continue to review Akorn s business affairs and general economic and industry conditions. Based upon such review, the Reporting Persons, will, on an on-going basis, evaluate various alternative courses of action including additional capital investments in Akorn. Alternatively, the Reporting Persons may sell all or a portion of their holdings in Akorn in the open market, subject to the requirements of Rule 144 or as otherwise permitted.

#### Item 5. Interest In Securities of the Issuer

- (a) See the Facing Page for each Reporting Person for information on the aggregate number and percentage of Akorn Common Stock held by each Reporting Person.
- (b) See the Facing Page for each Reporting Person as to the number of shares of Akorn Common Stock in which each Reporting Person has sole or shared voting or dispositive rights.
- (c) No transactions in Akorn Common Stock were effected by any of the Reporting Persons in the past 60 days except for the transactions described in Item 4.
- (d) Inapplicable.
- (e) Inapplicable.

#### Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The Modification Agreement described in Item 4 provides for the issuance of a Warrant for 1,939,639 shares of Akorn Common Stock. The Modification Agreement also provides for registration rights and the Warrant provides for standard anti-dilution protection. The Modification Agreement also gives EJ Funds LP the right to nominate two directors to serve on Akorn's Board of Directors, in addition to the right of the Trust to nominate a third director to serve on Akorn s Board of Directors (currently John N. Kapoor) under a Stock Purchase Agreement dated November 15, 1990 between Akorn and the Trust. It requires Akorn to amend its bylaws to increase the number of directors on the board from seven to nine and appoint the two additional designees. The Modification Agreement also requires that the designees be recommended by the Board of Directors at each shareholder election of directors and that all proxies be voted in favor of the election of the designees except as otherwise directed by any shareholder.

The Reimbursement Agreement referred to in Item 4, provides for the issuance of a Warrant in the amount of 1,501,933 shares of Akorn Common Stock in consideration for the provision of a letter of credit on behalf of Akorn by the Trust. It further provides that on each date of a draw under the letter of credit, an additional warrant shall be issued to the Trust for an aggregate number of shares of Akorn Common Stock equal to the product of (i) a quotient (carried to the ninth decimal place) equal to (A) the amount of such draw divided by (B) one million times (ii) 200,258. Shares acquired by exercise of this Warrant shall be covered by the registration rights in the Modification Agreement.

#### Item 7. Material to Be Filed as Exhibits

The following Exhibits are filed with this Amendment:

- 1. Modification, Registration and Investor Rights Agreement.
- 2. Reimbursement and Warrant Agreement.

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

April 20, 2009 /s/ John N. Kapoor John N. Kapoor

April 20, 2009 EJ FINANCIAL/AKORN MANAGEMENT, L.P.

By: Pharma Nevada, Inc., Managing General Partner

> /s/ John N. Kapoor John N. Kapoor, President

April 20, 2009 Pharma Nevada, Inc.

By: /s/ John N. Kapoor

John N. Kapoor, President

April 20, 2009 John N. Kapoor Trust

dtd 9/20/89

/s/ John N. Kapoor John N. Kapoor as Trustee

April 20, 2009 EJ Funds LP

By: EJ Financial Enterprises, Inc.

Its General Partner

By: /s/ John N. Kapoor

John N. Kapoor President

EXHIBIT A

AGREEMENT		
ТО		
JOINTLY FILE SCHEDULE 13D		
		rsigned hereby agree to jointly prepare and file with regulatory authorities this d's ownership of securities of Akorn, Inc., and hereby affirm that such Schedule
April 20, 2009		/s/ John N. Kapoor John N. Kapoor
April 20, 2009	EJ FIN	JANCIAL/AKORN MANAGEMENT, L.P.
	By:	Pharma Nevada, Inc., Managing General Partner
		/s/ John N. Kapoor John N. Kapoor, President
April 20, 2009	Pharm	a Nevada, Inc.
	Ву:	/s/ John N. Kapoor John N. Kapoor, President
April 20, 2009	John N dtd 9/2	I. Kapoor Trust 20/89
	Ву:	/s/ John N. Kapoor John N. Kapoor as Trustee
April 20, 2009	EJ Fur	nds LP
	By:	EJ Financial Enterprises, Inc. Its General Partner
	By:	/s/ John N. Kapoor

John N. Kapoor President